The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

被引：17

作者：

Ferraldeschi, Roberta ^{[1
,2
]}

Newman, William G. ^{[2
]}

机构：

[1] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England

[2] Univ Manchester, MAHSC, St Marys Hosp, Genet Med, Oxford Rd, Manchester M13 9WL, Lancs, England

来源：

PHARMACEUTICALS | 2010年 / 3卷 / 04期

关键词：

tamoxifen; CYP2D6; genotyping; breast cancer;

D O I：

10.3390/ph3041122

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.

引用

页码：1122 / 1138

页数：17

共 63 条

[1] No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications [J].

Ahern, Thomas P. ;

Pedersen, Lars ;

Cronin-Fenton, Deirdre P. ;

Sorensen, Henrik Toft ;

Lash, Timothy L. .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (09) :2562-2564

[2]

Aubert RE, 2009, J CLIN ONCOL, V27, p18S

[3] The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users [J].

Bijl, Monique J. ;

van Schaik, Ron H. N. ;

Lammers, Laureen A. ;

Hofman, Albert ;

Vulto, Arnold G. ;

van Gelder, Teun ;

Stricker, Bruno H. Ch. ;

Visser, Loes E. .

BREAST CANCER RESEARCH AND TREATMENT, 2009, 118 (01) :125-130

[4] Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment [J].

Borges, Silvana ;

Desta, Zeruesenay ;

Li, Lang ;

Skaar, Todd C. ;

Ward, Bryan A. ;

Nguyen, Anne ;

Jin, Yan ;

Storniolo, Anna Maria ;

Nikoloff, D. Michele ;

Wu, Lin ;

Hillman, Grant ;

Hayes, Daniel F. ;

Stearns, Vered ;

Flockhart, David A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :61-74

[5] CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants [J].

Bradford, LD .

PHARMACOGENOMICS, 2002, 3 (02) :229-243

[6] Pharmacogenomics of Tamoxifen Therapy [J].

Brauch, Hiltrud ;

Muerdter, Thomas E. ;

Eichelbaum, Michel ;

Schwab, Matthias .

CLINICAL CHEMISTRY, 2009, 55 (10) :1770-1782

[7] The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver [J].

Coller, JK ;

Krebsfaenger, N ;

Klein, K ;

Endrizzi, K ;

Wolbold, R ;

Lang, T ;

Nüssler, A ;

Neuhaus, P ;

Zanger, UM ;

Eichelbaum, M ;

Mürdter, TE .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (02) :157-167

[8] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6 [J].

Desta, Z ;

Ward, BA ;

Soukhova, NV ;

Flockhart, DA .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (03) :1062-1075

[9]

Dezentje V, 2009, J CLIN ONCOL S, V27, P509

[10] Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer [J].

Dezentje, Vincent O. ;

Guchelaar, Henk-Jan ;

Nortier, Johan W. R. ;

van de Velde, Cornelis J. H. ;

Gelderblom, Hans .

CLINICAL CANCER RESEARCH, 2009, 15 (01) :15-21

← 1 2 3 4 5 6 7 →